IMMUNOLOGICAL MARKERS OF INFLAMMATION IN PATIENTS WITH ASTHMA WITH SENSITIZATION TO ASPERGILLUS SPP.

DOI: https://doi.org/10.29296/25877305-2021-10-15
Download full text PDF
Issue: 
10
Year: 
2021

Associate Professor Ya. Kozlova, Candidate of Medical Sciences; E. Frolova, Candidate of
Medical Sciences; A. Uchevatkina, Candidate of Medical Sciences; L. Filippova, Candidate of Medical
Sciences; O. Aak, Candidate of Chemical Sciences; V. Kuznetsov; Professor N. Vasilyeva, Biol. Dr.; Professor
N. Klimko, MD North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg

Objective. To assess the level of traditional and additional markers of inflammation and to determine the features of the regulation of the immune response in patients with asthma with sensitization to Aspergillus spp. Materials and methods. The study included 57 patients with asthma without sensitization to Aspergillus spp., 36 patients with asthma with sensitization to Aspergillus spp., 25 patients with allergic bronchopulmonary aspergillosis (ABPA), 30 conditionally healthy individuals. The content of thymic stromal lymphopoietin (TSLP), thymus-associated regulatory chemokine (thymus andactivation-regulated chemokine; TARC), periostin, IL-8, levels of total IgE and specific IgE to Aspergillus spp. it was determined in the blood serum by the enzyme immunoassay. Results. In patients with asthma with sensitization to Aspergillus spp. significantly higher values of total IgE, sIgE to Aspergillus spp., and TARC levels in blood serum were established in comparison with patients with asthma. In the group of patients with ABPA, the values of the number of eosinophils, the levels of total IgE, sIgE to Aspergillus spp., TARC, periostin and IL-8 in the blood serum were significantly higher compared to patients with asthma. Significant differences in TARC levels were found in ABPA patients and asthma patients with Aspergillus spp sensitization. TSLP concentrations in the blood serum of the examined groups did not differ. Positive correlation of sIgE level to Aspergillus spp. with the content of TARC, periostin, IL-8 and the number of eosinophils, it confirms the importance of these markers in the development of allergic inflammation in patients with fungal sensitization. Conclusion. Increased levels of TARC and periostin, along with traditional biomarkers of eosinophilic inflammation, indicate activation of the Th2 type of immune response in asthma patients with Aspergillus spp sensitization.
Keywords: 
pulmonology
markers
Aspergillus spp.
allergic bronchopulmonary aspergillosis
asthma

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. 1. Rick E., Woolnough K., Pashley C. et al. Allergic Fungal Airway Disease. J Investig Allergol Clin Immunol. 2016; 26 (6): 344–54. DOI: 10.18176/jiaci.0122
  2. 2. Goh K., Ang Yii A., Lapperre T. et al. Sensitization to Aspergillus species is associated with frequent exacerbations in severe asthma. J Asthma Allergy. 2017; 10: 131–40. DOI: 10.2147/JAA.S130459
  3. 3. Denning D., O’Driscoll B., Hogaboam C. et al. The link between fungi and asthma: A summary of the evidence. Eur Respir J. 2006; 27 (3): 615–26. DOI: 10.1183/09031936.06.00074705
  4. 4. Agarwal R., Chakrabarti A., Shah A. et al. For the ABPA complicating asthma ISHAM working group 2013. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013; 43 (8): 850–73. DOI: 10.1111/cea.12141
  5. 5. Maurya V., Ghander Gugnani H., Usha Sarma P. et al. Sensitization to Aspergillus antigens and occurrence of allergic bronchopulmonary aspergillosis in patients with asthma. Chest. 2005; 127 (4): 1252–9. DOI: 10.1378/chest.127.4.1252
  6. 6. Agarwal R. Severe asthma with fungal sensitization. J Fungi. 2016; 2: 13–8.
  7. 7. Homma T., Kato A., Bhushan B. et al. Role of Aspergillus fumigatus in Triggering Protease-Activated Receptor-2 in Airway Epithelial Cells and Skewing the Cells toward a T-helper 2 Bias. Am J Respir Cell Mol Biol. 2016; 54 (1): 60–70. DOI: 10.1165/rcmb.2015-0062OC
  8. 8. Becker K., Gresnigt M., Smeekens S. et al. Pattern recognition pathways leading to a Th2 cytokine bias in allergic bronchopulmonary aspergillosis patients. Clin Exp Allergy. 2015; 45 (2): 423–37. DOI: 10.1111/cea.12354
  9. 9. Kozlov V.A., Savchenko A.A., Kudrjavtsev I.V. i dr. Klinicheskaja immunologija. Krasnojarsk: Polikor, 2020; 386 s. [Kozlov V.A., Savchenko A.A., Kudryavtsev I.V. et al. Clinical immunology. Krasnoyarsk: Polikor, 2020; 386 s. (in Russ.)]. DOI: 10.17513/np.438
  10. 10. Niespodziana K., Borochova K., Pazderova P. et al. Toward personalization of asthma treatment according to trigger factors. J Allergy Clin Immunol. 2020; 145 (6): 1529–34. DOI: 10.1016/j.jaci.2020.02.001
  11. 11. The Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2020. Available at: http://www.ginasthma.org [Accessed 19.05.2020]
  12. 12. Muraro A., Lemanske R., Hellings P. et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016; 137 (5): 1347–58. DOI: 10.1016/j.jaci.2016.03.010
  13. 13. Buhl R., Humbert M., Bjermer L. et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017; 49 (5): 1700634. DOI: 10.1183/13993003.00634-2017
  14. 14. Schleich F., Chevremont A., Paulus V. et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J. 2014; 44: 97–108. DOI: 10.1183/09031936.00201813
  15. 15. Nenasheva N.M. Bronhial'naja astma. Sovremennyj vzgljad na problemu. M.: GEOTAR-Media, 2018; 304 s. [Nenasheva N. Bronhial’naja astma. Sovremennyj vzgljad na problem. M.: GEOTAR-Media, 2018; 304 s. (in Russ.)].
  16. 16. Chai R., Liu B., Qi F. IL-31, IL-33, and TSLP expression and relation to severity of asthma and rhinitis in Chinese allergic patients. Int J Clin Exp Pathol. 2017; 10 (2): 1774–82.
  17. 17. Becerra-Diaz M., Wills-Karp M., Heller N. New perspectives on the regulation of type II inflammation in asthma. F1000Res. 2017; 6: 1014. DOI: 10.12688/f1000research.11198.1
  18. 18. Hartl D., Latzin P., Zissel G. et al. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med. 2006; 173 (12): 1370–6. DOI: 10.1164/rccm.200508-1271OC
  19. 19. Latzin P., Hartl D., Regamey N. et al. Comparison of serum markers for allergicbronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J. 2008; 31 (1): 36–42. DOI: 10.1183/09031936.00078107
  20. 20. Jia G., Erickson R., Choy D. et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012; 130 (3): 647–54. DOI: 10.1016/j.jaci.2012.06.025
  21. 21. Gibson P., Wark P., Simpson J. et al. Induced sputum IL-8 gene expression, neutrophil influx and MMP-9 in allergic bronchopulmonary aspergillosis. Eur Respir J. 2003; 21: 582–8. DOI: 10.1183/09031936.03.00001803